Ashkan Shoamanesh, MD; Robert G. Hart, MD; Stuart J. Connolly, MD; et al.
JAMA Neurol. 2021;78(1):11-20. doi:10.1001/jamaneurol.2020.3836
This prespecified analysis of a randomized clinical trial investigates the effect of cerebral microbleeds on patients with embolic stroke of undetermined source taking either daily rivaroxaban or aspirin.
Beom Joon Kim, MD, PhD; Bijoy K. Menon, MD, MSc; Jun Yup Kim, MD, MSc; et al.
JAMA Neurol. 2021;78(1):21-29. doi:10.1001/jamaneurol.2020.2804
This case-control study examines the prevalence of salvageable tissues 16 hours or more from the time the patient was last known well after ischemic stroke due to emergent large vessel occlusion and investigates the effectiveness of endovascular treatment in delayed large vessel occlusion.
Zerui Wang, MD, PhD; Katelyn Becker, MS; Vincenzo Donadio, MD, PhD; et al.
open access
JAMA Neurol. 2021;78(1):30-40. doi:10.1001/jamaneurol.2020.3311
This diagnostic study investigates sensitive and specific skin biomarkers for antemortem diagnosis of Parkinson disease and other synucleinopathies.
Kevin N. Sheth, MD; Mercy H. Mazurek, BS; Matthew M. Yuen, BA; et al.
JAMA Neurol. 2021;78(1):41-47. doi:10.1001/jamaneurol.2020.3263
This cohort study describes the outcomes of assessments of brain injury in patients with critical illness in intensive care units using a portable low-field magnetic resonance image device at the bedside, rather than a conventional imaging suite.
Bruce A. C. Cree, MD, PhD, MAS; Myla D. Goldman, MD, MSc; John R. Corboy, MD; et al.
open access
has active quiz
JAMA Neurol. 2021;78(1):48-60. doi:10.1001/jamaneurol.2020.2950
This randomized clinical trial evaluates the efficacy and safety of fingolimod, 0.5 mg, and fingolimod, 0.25 mg, compared with glatiramer acetate, 20 mg, and examines whether these fingolimod doses show superior efficacy to glatiramer acetate for the treatment of adult patients with relapsing-remitting multiple sclerosis.
Patryk Kubiszewski, BA; Lansing Sugita, BS; Christina Kourkoulis, BS; et al.
JAMA Neurol. 2021;78(1):61-67. doi:10.1001/jamaneurol.2020.3142
This study determines whether selective serotonin reuptake inhibitor use among survivors of primary intracerebral hemorrhage was associated with intracerebral hemorrhage recurrence and decreased severity of depressive symptoms.
Richard J. Barohn, MD; Byron Gajewski, PhD; Mamatha Pasnoor, MD; et al.
has active quiz
JAMA Neurol. 2021;78(1):68-76. doi:10.1001/jamaneurol.2020.2590
This randomized clinical trial examines which medication (pregabalin, duloxetine, nortriptyline, or mexiletine) is most effective for reducing neuropathic pain and best tolerated in patients with cryptogenic sensory polyneuropathy.
Shima Shahjouei, MD, MPH; Alireza Sadighi, MD; Durgesh Chaudhary, MD; et al.
JAMA Neurol. 2021;78(1):77-87. doi:10.1001/jamaneurol.2020.3627
This systematic review and meta-analysis calculates the pooled event rate for ischemic stroke within 2, 7, 30, and 90 days of a transient ischemic attack and compares this incidence among patients recruited before 1999, from 1999 to 2007, and after 2007.
Christopher D. Stephen, MB ChB, MRCP(UK), MS; Vicki Fung, PhD; Codrin I. Lungu, MD; et al.
has audio
JAMA Neurol. 2021;78(1):88-101. doi:10.1001/jamaneurol.2020.3753
This economic evaluation assesses US emergency department and inpatient use and charges for functional neurological disorders.
-
Audio Author Interview:
ED and Inpatient Use and Costs in Adult and Pediatric Functional Neurological Disorders
Brian W. Kunkle, PhD, MPH; Michael Schmidt, PhD; Hans-Ulrich Klein, PhD; et al.
JAMA Neurol. 2021;78(1):102-113. doi:10.1001/jamaneurol.2020.3536
This genome-wide association study identifies additional Alzheimer disease risk loci in African American individuals using the African Genome Resource panel.